25.95 USD
-0.12 (-0.46%)
25.95 USD
0 (0%)
AMPH gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. AMPH has an excellent profitability rating, but there are some minor concerns on its financial health. AMPH is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings could make AMPH a good candidate for value investing.
1. Profitability
1.1 Basic Checks
- In the past year AMPH was profitable.
- AMPH had a positive operating cash flow in the past year.
- AMPH had positive earnings in each of the past 5 years.
- In the past 5 years AMPH always reported a positive cash flow from operatings.
1.2 Ratios
- AMPH has a better Return On Assets (6.70%) than 87.96% of its industry peers.
- The Return On Equity of AMPH (14.37%) is better than 88.48% of its industry peers.
- AMPH has a better Return On Invested Capital (8.51%) than 86.91% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for AMPH is in line with the industry average of 12.84%.
- The last Return On Invested Capital (8.51%) for AMPH is well below the 3 year average (12.92%), which needs to be investigated, but indicates that AMPH had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.7% | ||
| ROE | 14.37% | ||
| ROIC | 8.51% |
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
1.3 Margins
- Looking at the Profit Margin, with a value of 15.43%, AMPH belongs to the top of the industry, outperforming 87.43% of the companies in the same industry.
- In the last couple of years the Profit Margin of AMPH has grown nicely.
- AMPH's Operating Margin of 20.73% is amongst the best of the industry. AMPH outperforms 87.96% of its industry peers.
- AMPH's Operating Margin has improved in the last couple of years.
- AMPH's Gross Margin of 49.36% is fine compared to the rest of the industry. AMPH outperforms 64.40% of its industry peers.
- In the last couple of years the Gross Margin of AMPH has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.73% | ||
| PM (TTM) | 15.43% | ||
| GM | 49.36% |
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AMPH is creating some value.
- AMPH has less shares outstanding than it did 1 year ago.
- AMPH has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, AMPH has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 2.39 indicates that AMPH is not a great score, but indicates only limited risk for bankruptcy at the moment.
- AMPH has a better Altman-Z score (2.39) than 62.30% of its industry peers.
- AMPH has a debt to FCF ratio of 5.49. This is a neutral value as AMPH would need 5.49 years to pay back of all of its debts.
- With an excellent Debt to FCF ratio value of 5.49, AMPH belongs to the best of the industry, outperforming 82.20% of the companies in the same industry.
- AMPH has a Debt/Equity ratio of 0.78. This is a neutral value indicating AMPH is somewhat dependend on debt financing.
- The Debt to Equity ratio of AMPH (0.78) is worse than 70.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | 5.49 | ||
| Altman-Z | 2.39 |
ROIC/WACC0.95
WACC8.92%
2.3 Liquidity
- A Current Ratio of 3.12 indicates that AMPH has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 3.12, AMPH is in line with its industry, outperforming 53.40% of the companies in the same industry.
- A Quick Ratio of 2.21 indicates that AMPH has no problem at all paying its short term obligations.
- With a Quick ratio value of 2.21, AMPH perfoms like the industry average, outperforming 46.60% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.21 |
3. Growth
3.1 Past
- The earnings per share for AMPH have decreased by -9.95% in the last year.
- AMPH shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 61.62% yearly.
- Looking at the last year, AMPH shows a decrease in Revenue. The Revenue has decreased by -0.03% in the last year.
- Measured over the past years, AMPH shows a quite strong growth in Revenue. The Revenue has been growing by 17.82% on average per year.
EPS 1Y (TTM)-9.95%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-3.12%
Revenue 1Y (TTM)-0.03%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%0.33%
3.2 Future
- Based on estimates for the next years, AMPH will show a small growth in Earnings Per Share. The EPS will grow by 0.14% on average per year.
- Based on estimates for the next years, AMPH will show a small growth in Revenue. The Revenue will grow by 4.14% on average per year.
EPS Next Y-8.73%
EPS Next 2Y-1.7%
EPS Next 3Y1.28%
EPS Next 5Y0.14%
Revenue Next Year-0.8%
Revenue Next 2Y1.99%
Revenue Next 3Y2.7%
Revenue Next 5Y4.14%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- AMPH is valuated cheaply with a Price/Earnings ratio of 7.54.
- Based on the Price/Earnings ratio, AMPH is valued cheaply inside the industry as 93.19% of the companies are valued more expensively.
- The average S&P500 Price/Earnings ratio is at 26.94. AMPH is valued rather cheaply when compared to this.
- A Price/Forward Earnings ratio of 6.96 indicates a rather cheap valuation of AMPH.
- Based on the Price/Forward Earnings ratio, AMPH is valued cheaply inside the industry as 92.67% of the companies are valued more expensively.
- The average S&P500 Price/Forward Earnings ratio is at 23.94. AMPH is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.54 | ||
| Fwd PE | 6.96 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AMPH indicates a rather cheap valuation: AMPH is cheaper than 91.62% of the companies listed in the same industry.
- AMPH's Price/Free Cash Flow ratio is rather cheap when compared to the industry. AMPH is cheaper than 90.58% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.74 | ||
| EV/EBITDA | 7.26 |
4.3 Compensation for Growth
- The excellent profitability rating of AMPH may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.12
EPS Next 2Y-1.7%
EPS Next 3Y1.28%
5. Dividend
5.1 Amount
- AMPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
25.95
-0.12 (-0.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners74.02%
Inst Owner Change0.15%
Ins Owners9.38%
Ins Owner Change-0.1%
Market Cap1.19B
Revenue(TTM)723.30M
Net Income(TTM)111.63M
Analysts78.33
Price Target32.2 (24.08%)
Short Float %11.77%
Short Ratio9.96
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.52%
Min EPS beat(2)10.58%
Max EPS beat(2)12.46%
EPS beat(4)3
Avg EPS beat(4)6.04%
Min EPS beat(4)-4.55%
Max EPS beat(4)12.46%
EPS beat(8)5
Avg EPS beat(8)4.79%
EPS beat(12)9
Avg EPS beat(12)18.2%
EPS beat(16)12
Avg EPS beat(16)16.54%
Revenue beat(2)1
Avg Revenue beat(2)0.23%
Min Revenue beat(2)-1.36%
Max Revenue beat(2)1.82%
Revenue beat(4)1
Avg Revenue beat(4)-1.21%
Min Revenue beat(4)-2.87%
Max Revenue beat(4)1.82%
Revenue beat(8)2
Avg Revenue beat(8)-0.96%
Revenue beat(12)6
Avg Revenue beat(12)0.35%
Revenue beat(16)9
Avg Revenue beat(16)0.62%
PT rev (1m)-1.34%
PT rev (3m)-4.91%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.91%
EPS NY rev (1m)-0.07%
EPS NY rev (3m)2.59%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.27%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.54 | ||
| Fwd PE | 6.96 | ||
| P/S | 1.65 | ||
| P/FCF | 10.74 | ||
| P/OCF | 7.83 | ||
| P/B | 1.54 | ||
| P/tB | 5.83 | ||
| EV/EBITDA | 7.26 |
EPS(TTM)3.44
EY13.26%
EPS(NY)3.73
Fwd EY14.37%
FCF(TTM)2.42
FCFY9.31%
OCF(TTM)3.31
OCFY12.77%
SpS15.74
BVpS16.9
TBVpS4.45
PEG (NY)N/A
PEG (5Y)0.12
Graham Number36.17
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.7% | ||
| ROE | 14.37% | ||
| ROCE | 10.26% | ||
| ROIC | 8.51% | ||
| ROICexc | 10.49% | ||
| ROICexgc | 20.29% | ||
| OM | 20.73% | ||
| PM (TTM) | 15.43% | ||
| GM | 49.36% | ||
| FCFM | 15.35% |
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
ROICexc(3y)16.46%
ROICexc(5y)13%
ROICexgc(3y)29.66%
ROICexgc(5y)21.24%
ROCE(3y)15.59%
ROCE(5y)12.24%
ROICexgc growth 3Y24.9%
ROICexgc growth 5YN/A
ROICexc growth 3Y2.33%
ROICexc growth 5YN/A
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
F-Score5
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | 5.49 | ||
| Debt/EBITDA | 3 | ||
| Cap/Depr | 78.19% | ||
| Cap/Sales | 5.71% | ||
| Interest Coverage | 6.36 | ||
| Cash Conversion | 75.12% | ||
| Profit Quality | 99.44% | ||
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.21 | ||
| Altman-Z | 2.39 |
F-Score5
WACC8.92%
ROIC/WACC0.95
Cap/Depr(3y)91.01%
Cap/Depr(5y)109.44%
Cap/Sales(3y)5.45%
Cap/Sales(5y)6.46%
Profit Quality(3y)95%
Profit Quality(5y)414.14%
High Growth Momentum
Growth
EPS 1Y (TTM)-9.95%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-3.12%
EPS Next Y-8.73%
EPS Next 2Y-1.7%
EPS Next 3Y1.28%
EPS Next 5Y0.14%
Revenue 1Y (TTM)-0.03%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%0.33%
Revenue Next Year-0.8%
Revenue Next 2Y1.99%
Revenue Next 3Y2.7%
Revenue Next 5Y4.14%
EBIT growth 1Y-30.02%
EBIT growth 3Y43.24%
EBIT growth 5YN/A
EBIT Next Year1.38%
EBIT Next 3Y0.74%
EBIT Next 5Y5.95%
FCF growth 1Y-20.6%
FCF growth 3Y34.69%
FCF growth 5Y286.43%
OCF growth 1Y-12.89%
OCF growth 3Y29.62%
OCF growth 5Y38.57%
AMPHASTAR PHARMACEUTICALS IN / AMPH FAQ
What is the fundamental rating for AMPH stock?
ChartMill assigns a fundamental rating of 6 / 10 to AMPH.
What is the valuation status of AMPHASTAR PHARMACEUTICALS IN (AMPH) stock?
ChartMill assigns a valuation rating of 8 / 10 to AMPHASTAR PHARMACEUTICALS IN (AMPH). This can be considered as Undervalued.
Can you provide the profitability details for AMPHASTAR PHARMACEUTICALS IN?
AMPHASTAR PHARMACEUTICALS IN (AMPH) has a profitability rating of 9 / 10.
What is the valuation of AMPHASTAR PHARMACEUTICALS IN based on its PE and PB ratios?
The Price/Earnings (PE) ratio for AMPHASTAR PHARMACEUTICALS IN (AMPH) is 7.54 and the Price/Book (PB) ratio is 1.54.